Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating ...
A Confirmed Partial Response in GEJ Patient, Stable Disease demonstrated in 75% of patients with mutated-KRAS colon cancer
Source: djournal.com
Stay updated with breaking news from Confirmed Partial Response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A Confirmed Partial Response in GEJ Patient, Stable Disease demonstrated in 75% of patients with mutated-KRAS colon cancer